NuGo Slim
US$ 27.66
glp 1 after gastric sleeve Interest in Treatment with GLP-1 Receptor Agonists for the Management of Insufficient Weight Loss or Weight Regain Bariatric Surgery | Obesity Surgery Bariatric Surgery vs. GLP-1s: Comparing
Description
Obesity and Type 2 Diabetes has an increasing prevalence worldwide, presenting a major health challenge
Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.
Although rare, associations with nonarteritic anterior ischemic optic neuropathy, pancreatitis, medullary thyroid carcinoma, and acute kidney injury (AKI) have been reported, primarily through pharmacovigilance and case-based evidence
This product does not contain synthetic GLP-1 and is not a GLP-1 agonist drug
However, its impact on appetite suppression soon became clear
